



(Use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 1 |
|-------|---|----|---|

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known

| | |
|------------------------|------------|
| Application Number | |
| Filing Date | 09/30/2005 |
| First Named Inventor | RUSSWURM |
| Art Unit | |
| Examiner Name | |
| Attorney Docket Number | 9740-1 |

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /STK/



PTO/SB/C8B (07-05)

Approved for use through 07/31/2006. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

USPTO form 1448/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Application Number

Filing Date

First Named Inventor

Art Unit

Examiner Name

Attorney Docket Number

Complete if Known

09/30/2005

RUSSWURM

9740-1

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials ¹ | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------------------|-----------------------|---|----------------|
| | | CHINNAIYAN et al., Molecular Signatures of Sepsis Multiorgan Gene Expression Profiles of Systemic Inflammation, Amer. J. Pathol., 159(4):1199-1209, 10/2001 | |
| | | YU et al., Differential gene expression in gram-negative and gram-positive sepsis, Am. J. Respir. Crit. Care Med., 169(10):1135-1143, 05/15/2004 | |
| | | SCHLAG et al., The cell in shock: the origin of multiple organ failure, Resuscitation, 21(2-3):137-180, 04/1991 | |
| | | PATHAN et al., The complexity of the inflammatory response to meningococcal sepsis revealed by gene expression profiling using cDNA microarrays, Critical Care Med., Bd. 30, Nr. 12, 12/2002 | |
| | | WIEGAND et al., Gene Expression Pattern in Human Monocytes as a Surrogate Marker for Systemic Inflammatory Response Syndrome (SIRS), Molecular Med., 5:192-202, 1999 | |
| | | PRUCHA et al., Expression Profiling: Toward an Application in Sepsis Diagnostics, Shock, 22(1):29-33, 07/2004 | |
| | | COBB et al., Sepsis gene expression profiling: Murine Splenic compared with hepatic responses determined by using complementary DNA microarrays, Crit. Care Med., 30(12):2711-2720, 12/2002 | |
| | | DEIGNER, Microarray expression profiling: towards an application in sepsis diagnostics, XP-002327554, www.sirs-lab.de/content/de/pdf/kompetenzen/deigner.pdf, 05/09/2005 | |
| | | MIRA et al., Association of TNF2, a TNF- α Promoter Polymorphism, with Septic Shock Susceptibility and Mortality, JAMA, 282(6):561-568, 08/11/1999 | |
| | | BARRIERE et al., An overview of mortality risk prediction in sepsis, Crit. Care Med., 23(2):376-393, 1995 | |

Examiner
Signature

/Stephen Kapushoc/

Date

Considered

02/09/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /STK/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | | | | | |
|-------|---|----|---|------------------------|------------|
| Sheet | 2 | of | 2 | Application Number | |
| | | | | Filing Date | 09/30/2005 |
| | | | | First Named Inventor | RUSSWURM |
| | | | | Art Unit | |
| | | | | Examiner Name | |
| | | | | Attorney Docket Number | 9740-1 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| | | BOWTELL, Options Available – From Start to Finish – for Obtaining Expression Data by Microarray, Nature Genetics Supplement, 21:25-32, 01/1999 | |
| | | MEMBERS OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS, Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis, Crit. Care Med, 20(6):864-874, 1992 | |
| | | HELLER et al., Discovery and Analysis of Inflammatory Disease-Related Genes Using cDNA Microarrays, Proc. Natl. Acad. Sci., 94:2150-2155, 03/1997 | |
| | | ROWE et al., An Array Immunosensor for Simultaneous Detection of Clinical Analytes, Anal. Chem., 71:433-439, 1999 | |
| | | KOSNY et al., Homo Sapiens (Clone KT2) Bone Morphogenetic Protein-1 (BMP-1) mRNA and Alternatively Spliced Mammalian Tollid Protein (mTld), XP002307377, European Molecular Biology Laboratory, Database Accession no. L35279, 01/18/1995 | |
| | | OBERHOFFER et al., Discriminative power of Inflammatory Markers for Prediction of Tumor Necrosis factor- α and Interleukin-6 in ICU Patients with Systemic Inflammatory Response Syndrome (SIRS) or Sepsis at Arbitrary Time Points, Int. Care Med, 26:S170-S174, 2000 | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Stephen Kapushoc/ | Date Considered | 02/09/2009 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial is reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.